Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1

The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who have not responded to prior therapy.

Inclusion Criteria:

• Male and female subjects ages 18 to 70 years
• HCV-Infected Genotype 1 Null responders to current standard of care
• Expansion Cohorts A1 and A2 are restricted to patients infected with HCV Genotype 1b only.

Exclusion Criteria:

• Evidence of a medical condition associate with chronic liver disease other than HCV
• History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis
• History of Cancer within 5 years of enrollment
• History of gastrointestinal disease or surgical procedure (except Cholecystectomy)
• History of clinically significant cardiac disease
• History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency
• Documented cirrhosis within 12 months prior to dosing
• Positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)
• Pregnant